Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma.
Future Oncol
; 13(1): 31-49, 2017 Jan.
Article
em En
| MEDLINE
| ID: mdl-27599260
ABSTRACT
AIM:
The study aim was to evaluate progression-free survival (PFS) and overall survival (OS) in patients with metastatic clear cell renal cell carcinoma on sunitinib (SU) and SU-everolimus treatment. PATIENTS &METHODS:
After 7 years of enrollment and 9 years of follow-up, 193 consecutively presenting patients (151 men and 42 women) were treated.RESULTS:
A total of 157 patients (81.3%) died and 36 patients (18.7%) survived. Median PFS in 193 SU-treated patients was 14.7 months and OS was 28.8 months. Median PFS was 13.98 months and median OS was 26.67 months in 175 patients treated with SU only or on SU-everolimus.CONCLUSION:
The development of SU-induced hypothyroidism, hypertension, neutropenia and edema was a significant predictive and prognostic factor.Palavras-chave
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pirróis
/
Carcinoma de Células Renais
/
Indóis
/
Neoplasias Renais
/
Antineoplásicos
Tipo de estudo:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Polônia